MedTrace Logo

Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria

NCT02614404 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-02-11

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and safety of imatinib in combination with dihydroartemisinin plus piperaquine in the treatment uncomplicated P. falciparum malaria in adult male patients.

Conditions

  • Plasmodium Falciparum Malaria

Interventions

DRUG

Imatinib combination therapy

Imatinib plus dihydroartemisinin plus piperaquine

DRUG

Dihydroartemisinin-piperaquine

Standard of care

Sponsors & Collaborators

  • Purdue University

    collaborator OTHER

  • University of Turin, Italy

    collaborator OTHER

  • Università degli Studi di Sassari

    collaborator OTHER

  • Hue University

    collaborator OTHER

  • HuLow

    lead INDUSTRY

Principal Investigators

  • Huynh D Chien, MD, PhD · Hue University

  • Francesco M Turrini, MD, PhD · University of Turin, Italy

  • Philip S Low, PhD · Purdue University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2016-12-02
Completion
2017-02-02

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02614404 on ClinicalTrials.gov